Bal Pharma Limited has submitted a regulatory filing to the National Stock Exchange of India Limited and BSE Limited regarding an upcoming board meeting.
The meeting of the Board of Directors is scheduled to be held on Wednesday, August 12, 2026. The primary agenda for the meeting includes considering and approving the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 (Q1 of financial year 2026-27).
The disclosure states that the board may also consider "such other matters as may be considered necessary with the permission of the Chair."
The document was digitally signed by Shreepada ML, who is identified as the Company Secretary and Compliance Officer of Bal Pharma Limited, with ICSI membership number A66681.